The DOI matches its Crossref record; 81 of the 81 references it cites were found in a registry or an index.
The coming of age of virus-like particle vaccines
Abstract
Virus-like particles are supra-molecular assemblages, usually icosahedral or rod-like structures. They incorporate key immunologic features of viruses which include repetitive surfaces, particulate structures and induction of innate immunity through activation of pathogen-associated molecular-pattern recognition receptors. They carry no replicative genetic information and can be produced recombinantly in large scale. Virus-like particles thus represent a safe and effective vaccine platform for inducing potent B- and T-cell responses. In addition to being effective vaccines against the corresponding virus from which they are derived, virus-like particles can also be used to present foreign epitopes to the immune system. This can be achieved by genetic fusion or chemical conjugation. This technological innovation has greatly broadened the scope of their use, from immunizing against microbial pathogens to immunotherapy for chronic diseases. Towards this end, virus-like particles have been used to induce autoantibodies to disease-associated self-molecules involved in chronic diseases, such as hypertension and Alzheimer's disease. The recognition of the potent immunogenicity and commercial potential for virus-like particles has greatly accelerated research and development activities. During the last decade, two prophylactic virus-like particle vaccines have been registered for human use, while another 12 vaccines entered clinical development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse
Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., et al. (1999) · Nature · doi:10.1038/22124 · Cited by 3,160
Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases
Garland, S. M., Hernandez-Avila, M., Wheeler, C. M., Perez, G., Harper, D. M., Leodolter, S., Tang, G. W. K., Ferris, D. G., Steben, M., Bryan, J., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa061760 · Cited by 1,886
Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report
Nicoll, J. A. R., Wilkinson, D., Holmes, C., Steart, P., Markham, H., & Weller, R. O. (2003) · Nature Medicine · doi:10.1038/nm840 · Cited by 1,397
Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial
Gilman, S., Koller, M., Black, R. S., Jenkins, L., Griffith, S. G., Fox, N. C., Eisner, L., Kirby, L., Rovira, M. B., Forette, F., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000159740.16984.3c · Cited by 1,329
Paavonen, J., Jenkins, D., Bosch, F. X., Naud, P., Salmerón, J., Wheeler, C. M., Chow, S.-N., Apter, D. L., Kitchener, H. C., Castellsague, X., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60946-5 · Cited by 1,315
Therapeutic potential of Toll-like receptor 9 activation
Krieg, A. M. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2059 · Cited by 1,246
Worldwide prevalence of hypertension: a systematic review
Kearney, P. M., Whelton, M., Reynolds, K., Whelton, P. K., & He, J. (2004) · Journal of Hypertension · doi:10.1097/00004872-200401000-00003 · Cited by 1,140
Kirnbauer, R., Booy, F., Cheng, N., Lowy, D. R., & Schiller, J. T. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.24.12180 · Cited by 1,110
Expression, self-assembly, and antigenicity of the Norwalk virus capsid protein
Jiang, X., Wang, M., Graham, D. Y., & Estes, M. K. (1992) · Journal of Virology · doi:10.1128/jvi.66.11.6527-6532.1992 · Cited by 860
A universal influenza A vaccine based on the extracellular domain of the M2 protein
Neirynck, S., Deroo, T., Saelens, X., Vanlandschoot, P., Jou, W. M., & Fiers, W. (1999) · Nature Medicine · doi:10.1038/13484 · Cited by 752
The Influence of Antigen Organization on B Cell Responsiveness
Bachmann, M. F., Rohrer, U. H., Kündig, T. M., Bürki, K., Hengartner, H., & Zinkernagel, R. M. (1993) · Science · doi:10.1126/science.8248784 · Cited by 717
Self-citationSize-Dependent Immunogenicity: Therapeutic and Protective Properties of Nano-Vaccines against Tumors
Fifis, T., Gamvrellis, A., Crimeen-Irwin, B., Pietersz, G. A., Li, J., Mottram, P. L., McKenzie, I. F. C., & Plebanski, M. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.5.3148 · Cited by 664
Vaccines: past, present and future
Plotkin, S. A. (2005) · Nature Medicine · doi:10.1038/nm1209 · Cited by 592
Kovacsovics-Bankowski, M., Clark, K., Benacerraf, B., & Rock, K. L. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.11.4942 · Cited by 591
Virus-like particles: Passport to immune recognition
Grgacic, E. V. L., & Anderson, D. A. (2006) · Methods · doi:10.1016/j.ymeth.2006.07.018 · Cited by 582
Ahsan, F. (2002) · Journal of Controlled Release · doi:10.1016/s0168-3659(01)00549-1 · Cited by 570
Human Immune Responses to a Novel Norwalk Virus Vaccine Delivered in Transgenic Potatoes
Tacket, C. O., Mason, H. S., Losonsky, G., Estes, M. K., Levine, M. M., & Arntzen, C. J. (2000) · The Journal of Infectious Diseases · doi:10.1086/315653 · Cited by 481
NEUTRALIZING ANTIVIRAL B CELL RESPONSES
Bachmann, M. F., & Zinkernagel, R. M. (1997) · Annual Review of Immunology · doi:10.1146/annurev.immunol.15.1.235 · Cited by 471
Self-citationJegerlehner, A., Schmitz, N., Storni, T., & Bachmann, M. F. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.9.5598 · Cited by 397
Self-citationHarding, C. V., & Song, R. (1994) · The Journal of Immunology · doi:10.4049/jimmunol.153.11.4925 · Cited by 383
Aβ vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease
Masliah, E., Hansen, L., Adame, A., Crews, L., Bard, F., Lee, C., Seubert, P., Games, D., Kirby, L., & Schenk, D. (2005) · Neurology · doi:10.1212/01.wnl.0000148590.39911.df · Cited by 353
Recognition of viruses by innate immunity
Takeuchi, O., & Akira, S. (2007) · Immunological Reviews · doi:10.1111/j.1600-065x.2007.00562.x · Cited by 342
Gordon, D. M., McGovern, T. W., Krzych, U., Cohen, J. C., Schneider, I., LaChance, R., Heppner, D. G., Yuan, G., Hollingdale, M., Slaoui, M., et al. (1995) · Journal of Infectious Diseases · doi:10.1093/infdis/171.6.1576 · Cited by 327
Virus-like particles: flexible platforms for vaccine development
Chackerian, B. (2007) · Expert Review of Vaccines · doi:10.1586/14760584.6.3.381 · Cited by 321
Storni, T., Ruedl, C., Schwarz, K., Schwendener, R. A., Renner, W. A., & Bachmann, M. F. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.3.1777 · Cited by 286
Self-citationTissot, A. C., Maurer, P., Nussberger, J., Sabat, R., Pfister, T., Ignatenko, S., Volk, H.-D., Stocker, H., Müller, P., Jennings, G. T., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60381-5 · Cited by 286
Self-citationMaurer, P., Jennings, G. T., Willers, J., Rohner, F., Lindman, Y., Roubicek, K., Renner, W. A., Müller, P., & Bachmann, M. F. (2005) · European Journal of Immunology · doi:10.1002/eji.200526285 · Cited by 279 · cited 3×
“The resultant vaccine, containing approximately 580 nicotine molecules per VLP particle, was used to establish safety and immunogenicity in a phase I clinical trial in non-smokers (Maurer et al., 2005).”
BackgroundMethodHBV Core Particles as a Carrier for B Cell/T Cell Epitopes
Pumpens, P., & Grens, E. (2001) · Intervirology · doi:10.1159/000050037 · Cited by 274
TLR9 Signaling in B Cells Determines Class Switch Recombination to IgG2a
Jegerlehner, A., Maurer, P., Bessa, J., Hinton, H. J., Kopf, M., & Bachmann, M. F. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.4.2415 · Cited by 273
Self-citationPapillomavirus-Like Particles Induce Acute Activation of Dendritic Cells
Lenz, P., Day, P. M., Pang, Y.-Y. S., Frye, S. A., Jensen, P. N., Lowy, D. R., & Schiller, J. T. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.9.5346 · Cited by 252
Chackerian, B., Lowy, D. R., & Schiller, J. T. (2001) · Journal of Clinical Investigation · doi:10.1172/jci11849 · Cited by 251
Native display of complete foreign protein domains on the surface of hepatitis B virus capsids
Kratz, P. A., Böttcher, B., & Nassal, M. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.5.1915 · Cited by 248
Humoral, mucosal, and cellular immune responses to oral Norwalk virus-like particles in volunteers
Tacket, C. O., Sztein, M. B., Losonsky, G. A., Wasserman, S. S., & Estes, M. K. (2003) · Clinical Immunology · doi:10.1016/s1521-6616(03)00120-7 · Cited by 238
Type I (CD64) and type II (CD32) Fc γ receptor-mediated phagocytosis by human blood dendritic cells
Fanger, N. A., Wardwell, K., Shen, L., Tedder, T. F., & Guyre, P. M. (1996) · The Journal of Immunology · doi:10.4049/jimmunol.157.2.541 · Cited by 236
Treanor, J. J., Tierney, E. L., Zebedee, S. L., Lamb, R. A., & Murphy, B. R. (1990) · Journal of Virology · doi:10.1128/jvi.64.3.1375-1377.1990 · Cited by 233
Recombinant Norwalk virus–like particles given orally to volunteers: Phase I study
Ball, J. M., Graham, D. Y., Opekun, A. R., Gilger, M. A., Guerrero, R. A., & Estes, M. K. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70548-2 · Cited by 227
JEGERLEHNER, A. (2002) · Vaccine · doi:10.1016/s0264-410x(02)00266-9 · Cited by 226
Changes in heroin self-administration by a rhesus monkey after morphine immunisation
BONESE, K. F., WAINER, B. H., FITCH, F. W., ROTHBERG, R. M., & SCHUSTER, C. R. (1974) · Nature · doi:10.1038/252708a0 · Cited by 220
Ambühl, P. M., Tissot, A. C., Fulurija, A., Maurer, P., Nussberger, J., Sabat, R., Nief, V., Schellekens, C., Sladko, K., Roubicek, K., et al. (2007) · Journal of Hypertension · doi:10.1097/hjh.0b013e32800ff5d6 · Cited by 219
Self-citationThe influence of virus structure on antibody responses and virus serotype formation
Bachmann, M. F., & Zinkernagel, R. M. (1996) · Immunology Today · doi:10.1016/s0167-5699(96)10066-9 · Cited by 204
Self-citationFicolins and the lectin complement pathway
Matsushita, M., & Fujita, T. (2001) · Immunological Reviews · doi:10.1034/j.1600-065x.2001.1800107.x · Cited by 203
Vaccination against IL‐17 suppresses autoimmune arthritis and encephalomyelitis
Röhn, T. A., Jennings, G. T., Hernandez, M., Grest, P., Beck, M., Zou, Y., Kopf, M., & Bachmann, M. F. (2006) · European Journal of Immunology · doi:10.1002/eji.200636658 · Cited by 195
Self-citationNatural Supramolecular Building Blocks
Wang, Q., Lin, T., Johnson, J. E., & Finn, M. G. (2002) · Chemistry & Biology · doi:10.1016/s1074-5521(02)00166-7 · Cited by 192
Pentel, P. R., Malin, D. H., Ennifar, S., Hieda, Y., Keyler, D. E., Lake, J. R., Milstein, J. R., Basham, L. E., Coy, R. T., Moon, J. W. D., et al. (2000) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(99)00206-3 · Cited by 179
Bachmann, M. F., Hengartner, H., & Zinkernagel, R. M. (1995) · European Journal of Immunology · doi:10.1002/eji.1830251236 · Cited by 176
Self-citationNeutralization of IL‐17 by active vaccination inhibits IL‐23‐dependent autoimmune myocarditis
Sonderegger, I., Röhn, T. A., Kurrer, M. O., Iezzi, G., Zou, Y., Kastelein, R. A., Bachmann, M. F., & Kopf, M. (2006) · European Journal of Immunology · doi:10.1002/eji.200636484 · Cited by 167
Self-citationImmunotherapy for Alzheimer's disease
Gélinas, D. S., Silva, K. D., Fenili, D., George‐Hyslop, P. S., & McLaurin, J. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0404866101 · Cited by 162
Role of Toll‐like receptors in costimulating cytotoxic T cell responses
Schwarz, K., Storni, T., Manolova, V., Didierlaurent, A. M., Sirard, J., Röthlisberger, P., & Bachmann, M. F. (2003) · European Journal of Immunology · doi:10.1002/eji.200323919 · Cited by 155
Self-citationHepatitis B vaccines: assessment of the seroprotective efficacy of two recombinant DNA vaccines
Coates, T., Wilson, R., Patrick, G., André, F., & Watson, V. (2001) · Clinical Therapeutics · doi:10.1016/s0149-2918(01)80044-8 · Cited by 147
Core Particles of Hepatitis B Virus as Carrier for Foreign Epitopes
Ulrich, R., Nassal, M., Meisel, H., & Krüger, D. H. (1998) · Advances in virus research · doi:10.1016/s0065-3527(08)60808-8 · Cited by 141
Role of Repetitive Antigen Patterns for Induction of Antibodies Against Antibodies
Fehr, T. H., Bachmann, M. F., Bucher, E. M., Kalinke, U., Padova, F. E. D., Lang, A. B., Hengartner, H., & Zinkernagel, R. M. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.185.10.1785 · Cited by 135
Self-citationRuedl, C., Storni, T., Lechner, F., Bächi, T., & Bachmann, M. F. (2002) · European Journal of Immunology · Cited by 127
Self-citationThe Economic Impact of Hypertension
Elliott, W. J. (2003) · Journal of Clinical Hypertension · doi:10.1111/j.1524-6175.2003.02463.x · Cited by 125
Storni, T., Lechner, F., Erdmann, I., Bächi, T., Jegerlehner, A., Dumrese, T., Kündig, T. M., Ruedl, C., & Bachmann, M. F. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.6.2880 · Cited by 119
Self-citationBrown, M. J., Coltart, J., Gunewardena, K. A., Ritter, J. M., Auton, T. R., & Glover, J. F. (2004) · Clinical Science · doi:10.1042/cs20030381 · Cited by 118
Induction of autoantibodies to mouse CCR5 with recombinant papillomavirus particles
Chackerian, B., Lowy, D. R., & Schiller, J. T. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.5.2373 · Cited by 117
Structures of virus and virus-like particles
Johnson, J. (2000) · Current Opinion in Structural Biology · doi:10.1016/s0959-440x(00)00073-7 · Cited by 112
Chackerian, B., Rangel, M., Hunter, Z. N., & Peabody, D. S. (2006) · Vaccine · doi:10.1016/j.vaccine.2006.05.059 · Cited by 110
Spohn, G., Guler, R., Johansen, P., Keller, I., Jacobs, M., Beck, M., Röhner, F., Bauer, M., Dietmeier, K., Kündig, T. M., et al. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.11.7450 · Cited by 110
Self-citationActive Immunization against Nicotine Prevents Reinstatement of Nicotine-Seeking Behavior in Rats
Lindblom, N., de Villiers, S. H. L., Kalayanov, G., Gordon, S. L., Johansson, A. M., & Svensson, T. H. (2002) · Respiration · doi:10.1159/000063629 · Cited by 106
Nardin, E. H., Oliveira, G. A., Calvo‐Calle, J. M., Wetzel, K., Maier, C., Birkett, A. J., Sarpotdar, P. P., Corado, M. L., Thornton, G. B., & Schmidt, A. (2004) · Infection and Immunity · doi:10.1128/iai.72.11.6519-6527.2004 · Cited by 99
Active immunization with IL‐1 displayed on virus‐like particles protects from autoimmune arthritis
Spohn, G., Keller, I., Beck, M., Grest, P., Jennings, G. T., & Bachmann, M. F. (2008) · European Journal of Immunology · doi:10.1002/eji.200737989 · Cited by 89
Self-citationActive Immunization Alters the Plasma Nicotine Concentration in Rats
Hieda, Y., Keyler, D. E., VanDeVoort, J. T., Kane, J. K., Ross, C. A., Raphael, D. E., Niedbalas, R. S., & Pentel, P. R. (1997) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37155-1 · Cited by 89
Rapid Response of Marginal Zone B Cells to Viral Particles
Gatto, D., Ruedl, C., Odermatt, B. F., & Bachmann, M. F. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.7.4308 · Cited by 81
Self-citationde Villiers, S. H. L., Lindblom, N., Kalayanov, G., Gordon, S. L., Malmerfelt, A., Johansson, A. M., & Svensson, T. H. (2002) · Respiration · doi:10.1159/000063628 · Cited by 81
Dintzis, R. Z., Vogelstein, B., & Dintzis, H. M. (1982) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.79.3.884 · Cited by 72
Papillomavirus-Like Particle Vaccines
Schiller, J. T., & Lowy, D. R. (2000) · JNCI Monographs · doi:10.1093/oxfordjournals.jncimonographs.a024258 · Cited by 72
Efficient homologous prime‐boost strategies for T cell vaccination based on virus‐like particles
Schwarz, K., Meijerink, E., Speiser, D. E., Tissot, A. C., Cielēns, I., Renhof, R., Dišlers, A., Pumpens, P., & Bachmann, M. F. (2005) · European Journal of Immunology · doi:10.1002/eji.200425755 · Cited by 69
Self-citationA Viral Platform for Chemical Modification and Multivalent Display
Peabody, D. S. (2003) · Journal of Nanobiotechnology · doi:10.1186/1477-3155-1-5 · Cited by 68
Storni, T., & Bachmann, M. F. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.10.6129 · Cited by 66
Self-citationLong-term compliance with antihypertensive therapy
Burnier, M. (2000) · Blood Pressure Monitoring · doi:10.1097/00126097-200005001-00006 · Cited by 65
Polyvalent Antigens Stabilize B Cell Antigen Receptor Surface Signaling Microdomains
Thyagarajan, R., Arunkumar, N., & Song, W. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.12.6099 · Cited by 60
Virus-Like Particles as a Modular System for Novel Vaccines
Lechner, F., Jegerlehner, A., Tissot, A. C., Maurer, P., Sebbel, P., Renner, W. A., Jennings, G. T., & Bachmann, M. F. (2002) · Intervirology · doi:10.1159/000067912 · Cited by 59
Self-citationSpohn, G., Schwarz, K., Maurer, P., Illges, H., Rajasekaran, N., Choi, Y., Jennings, G. T., & Bachmann, M. F. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.9.6211 · Cited by 58
Self-citationA One-Size-Fits-All Flu Vaccine?
Kaiser, J. (2006) · Science · doi:10.1126/science.312.5772.380 · Cited by 57
Passive immunization against nicotine prevents nicotine alleviation of nicotine abstinence syndrome
Malin, D. H., Lake, J. R., Lin, A., Saldaña, M., Balch, L., Irvin, M. L. L., Chandrasekara, H., Alvarado, C. L., Hieda, Y., Keyler, D. E., et al. (2001) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(00)00436-6 · Cited by 56
Zamora, E. D., Handisurya, A., Shafti‐Keramat, S., Borchelt, D., Rudow, G. L., Conant, K. E., Cox, C., Troncoso, J. C., & Kirnbauer, R. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.4.2662 · Cited by 51
Influenza vaccines: a review and rationale for use in developed and underdeveloped countries
Poland, G. A., Rottinghaus, S. T., & Jacobson, R. M. (2001) · Vaccine · doi:10.1016/s0264-410x(00)00448-5 · Cited by 49
Lindenburg, C. E. A., Stolte, I. G., Langendam, M. W., Miedema, F. F., Williams, I. G., Colebunders, R., Weber, J. N., Fisher, M., & Coutinho, R. A. (2002) · Vaccine · doi:10.1016/s0264-410x(02)00102-0 · Cited by 35
Therapeutic vaccines for nicotine dependence.
Maurer, P., & Bachmann, M. F. (2006) · PubMed · Cited by 29
Self-citationThe genetics of human hypertension
Crook, E. D. (2002) · Seminars in Nephrology · doi:10.1053/snep.2002.28641 · Cited by 17
Cited by
Vaccine adjuvants: mechanisms and platforms
Zhao, T., Cai, Y., Jiang, Y., He, X., Wei, Y., Yu, Y., & Tian, X. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01557-7 · Cited by 1,020
Virus-like particles in vaccine development
Roldão, A., Mellado, M. C. M., Castilho, L. R., Carrondo, M. J., & Alves, P. M. (2010) · Expert Review of Vaccines · doi:10.1586/erv.10.115 · Cited by 845
Cell-free protein synthesis: Applications come of age
Carlson, E. D., Gan, R., Hodgman, C. E., & Jewett, M. C. (2012) · Biotechnology Advances · doi:10.1016/j.biotechadv.2011.09.016 · Cited by 706
Major findings and recent advances in virus–like particle (VLP)-based vaccines
Mohsen, M. O., Zha, L., Cabral-Miranda, G., & Bachmann, M. F. (2017) · Seminars in Immunology · doi:10.1016/j.smim.2017.08.014 · Cited by 555
Self-citationProtein Assembly: Versatile Approaches to Construct Highly Ordered Nanostructures
Luo, Q., Hou, C., Bai, Y., Wang, R., & Liu, J. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00228 · Cited by 542
Metadata
- Authors
- Jennings, G. T., & Bachmann, M. F.
- Venue
- bchm
- Publisher
- Walter de Gruyter GmbH
- Published
- 2008-03-27
- Volume
- 389
- Issue
- 5
- Pages
- 521-536
- ISSN
- 1431-6730 (ISSN-L)
- 1437-4315
- OpenAlex
- W1987519563
- Cited by
- 369
- References
- 81
- FWCI
- 8.84
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.